Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2024-07-30 Regulatory Filings
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings
2024-07-30 English
La CNMV ha decidido levantar la suspensión de Grifols, S.A. con efecto de las 16:45 horas de hoy.
Regulatory Filings Classification · 98% confidence The document is a formal communication from the Spanish National Securities Market Commission (CNMV) dated July 30, 2024. The core content is the decision to lift a precautionary suspension of trading for GRIFOLS, S.A. shares and related instruments. It includes a structured notification table conforming to EU Regulation 2017/1005, detailing the action type as 'Levantamiento de suspensión' (Lifting of suspension) due to the release of privileged information. This type of official, non-periodic regulatory announcement that doesn't fit into specific categories like earnings, director dealings, or capital changes is best classified as a general Regulatory Filing or Announcement. Since 'Regulatory Filings' (RNS) is the defined fallback for miscellaneous regulatory announcements, and this is a specific regulatory action notice, RNS is the most appropriate code.
2024-07-30 Spanish
Grifols anuncia los resultados financieros del segundo trimestre de 2024
Earnings Release Classification · 98% confidence The document is titled "Resultados 2T 2024" (2Q 2024 Results) and contains detailed financial performance metrics for the second quarter and first half of 2024, including revenue growth, adjusted EBITDA, margins, and cash flow reconciliation. It explicitly discusses financial performance, guidance reiteration, and business analysis, which are hallmarks of an earnings report. Although it is a presentation format (suggesting it could be an Investor Presentation (IP)), the core content is the official release of period-specific financial results, which aligns most closely with an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it covers the full quarterly results and includes detailed financial tables and management commentary on the period's performance, it functions as the primary release of those results. Given the context of reporting specific quarterly financial figures ('Resultados del segundo trimestre de 2024'), it is classified as an Interim/Quarterly Report (IR), which is typically more comprehensive than a brief Earnings Release (ER). The document length (88,444 chars) confirms it is substantial, not just a short announcement (ruling out RPA/RNS based on the 'MENU VS MEAL' rule for short announcements). Q2 2024
2024-07-30 Spanish
FORM 6-K
Regulatory Filings
2024-07-19 English
Designación de asesores financieros de los consejeros no conflictuados y del Comité de la Transacción y acuerdo de confidencialidad con Brookfield.
M&A Activity Classification · 98% confidence The document is a formal communication from Grifols, S.A., referencing Spanish securities law (Ley 6/2023, artículo 227) and titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It discusses the appointment of financial advisors (Morgan Stanley and Goldman Sachs) and the approval of a confidentiality agreement with Brookfield regarding a potential acquisition offer ('oferta de adquisición por la totalidad de las acciones de la Sociedad'). This content strongly relates to corporate actions, specifically potential M&A activity or significant financing/transaction structuring, which falls under the scope of major corporate events requiring regulatory disclosure. Reviewing the definitions: - 10-K/IR: Not a full annual or interim report. - ER/MRQ: Not an earnings release or major shareholding notification. - CAP: While related to financing/capital structure, the core topic is the process surrounding a potential takeover/acquisition. - TAR (M&A Activity): This category covers 'merger proposals or takeover bids.' The document explicitly discusses steps taken in relation to a 'Transacción' that could lead to an 'oferta de adquisición por la totalidad de las acciones de la Sociedad' (an offer to acquire all shares). - RNS (Regulatory Filings): This is a general fallback. Since the content directly addresses the preparatory steps for a potential takeover/acquisition, TAR is a more specific fit than RNS. Given the focus on facilitating a potential acquisition offer by an external party (Brookfield), the classification should be M&A Activity (TAR). The document is a formal disclosure of steps taken regarding this potential transaction.
2024-07-19 Spanish
FORM 6-K
Regulatory Filings
2024-07-16 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.